Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q4 and full year 2025 on February 5, 2026, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system's genetics to enhance its diagnostic and therapeutic capabilities [3] - Its proprietary immune medicine platform is designed to partner with biopharmaceutical companies and develop clinical diagnostics in two segments: Minimal Residual Disease (MRD) and Immune Medicine [3] - The company’s products and clinical pipeline target diseases such as cancer and autoimmune disorders, with a goal of creating personalized immune-driven clinical products [3]